Download
s12874-021-01218-9.pdf 1,28MB
WeightNameValue
1000 Titel
  • Phase I dose-escalation oncology trials with sequential multiple schedules
1000 Autor/in
  1. Günhan, Burak Kürsad |
  2. Weber, Sebastian |
  3. Seroutou, Abdelkader |
  4. Friede, Tim |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-04-14
1000 Erschienen in
1000 Quellenangabe
  • 21(1):69
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12874-021-01218-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045405/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Conventional methods for phase I dose-escalation trials in oncology are based on a single treatment schedule only. More recently, however, multiple schedules are more frequently investigated in the same trial.!##!Methods!#!Here, we consider sequential phase I trials, where the trial proceeds with a new schedule (e.g. daily or weekly dosing) once the dose escalation with another schedule has been completed. The aim is to utilize the information from both the completed and the ongoing schedules to inform decisions on the dose level for the next dose cohort. For this purpose, we adapted the time-to-event pharmacokinetics (TITE-PK) model, which were originally developed for simultaneous investigation of multiple schedules. TITE-PK integrates information from multiple schedules using a pharmacokinetics (PK) model.!##!Results!#!In a simulation study, the developed approach is compared to the bridging continual reassessment method and the Bayesian logistic regression model using a meta-analytic-predictive prior. TITE-PK results in better performance than comparators in terms of recommending acceptable dose and avoiding overly toxic doses for sequential phase I trials in most of the scenarios considered. Furthermore, better performance of TITE-PK is achieved while requiring similar number of patients in the simulated trials. For the scenarios involving one schedule, TITE-PK displays similar performance with alternatives in terms of acceptable dose recommendations. The R and Stan code for the implementation of an illustrative sequential phase I trial example in oncology is publicly available ( https://github.com/gunhanb/TITEPK_sequential ).!##!Conclusion!#!In phase I oncology trials with sequential multiple schedules, the use of all relevant information is of great importance. For these trials, the adapted TITE-PK which combines information using PK principles is recommended.
1000 Sacherschließung
lokal Dose-Response Relationship, Drug [MeSH]
lokal Medical Oncology [MeSH]
lokal Humans [MeSH]
lokal Bayesian statistics
lokal Computer Simulation [MeSH]
lokal Bayes Theorem [MeSH]
lokal Research Design [MeSH]
lokal Data analysis, statistics and modelling
lokal Multiple treatment schedules
lokal PK models
lokal Phase I dose-escalation trials
lokal Neoplasms/drug therapy [MeSH]
lokal Maximum Tolerated Dose [MeSH]
lokal Research Article
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-7454-8680|https://frl.publisso.de/adhoc/uri/V2ViZXIsIFNlYmFzdGlhbg==|https://frl.publisso.de/adhoc/uri/U2Vyb3V0b3UsIEFiZGVsa2FkZXI=|https://orcid.org/0000-0001-5347-7441
1000 Hinweis
  • DeepGreen-ID: 5a1e1308df42473a99d75fa4086c923a ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6465241.rdf
1000 Erstellt am 2023-11-16T11:37:18.573+0100
1000 Erstellt von 322
1000 beschreibt frl:6465241
1000 Zuletzt bearbeitet 2023-12-01T01:52:25.169+0100
1000 Objekt bearb. Fri Dec 01 01:52:25 CET 2023
1000 Vgl. frl:6465241
1000 Oai Id
  1. oai:frl.publisso.de:frl:6465241 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source